Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib
Y Zhang, Y Cai, SR Zhang, CY Li, LL Jiang, P Wei… - Toxicology Letters, 2021 - Elsevier
Aims Both gefitinib and afatinib are epidermal growth factor tyrosine kinase inhibitors (EGFR-
TKI) in the treatment of non-small cell lung cancer (NSCLC). It has been reported that …
TKI) in the treatment of non-small cell lung cancer (NSCLC). It has been reported that …
[HTML][HTML] Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
AF AlAsmari, N Ali, F AlAsmari, WA AlAnazi… - Saudi Pharmaceutical …, 2020 - Elsevier
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
[HTML][HTML] Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer
F Teng, J Xu, J Wang, B Yang, YZ Wu, YQ Jiang… - Frontiers in …, 2023 - frontiersin.org
Objective: To understand the characteristics of genetic mutation in multiple primary lung
cancer so as to guide clinical decisions in targeted therapy. Methods: We analyzed a total of …
cancer so as to guide clinical decisions in targeted therapy. Methods: We analyzed a total of …
Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non–small-cell lung cancer
RGP Gijtenbeek, RAM Damhuis, HJM Groen… - Clinical lung cancer, 2020 - Elsevier
Background Only a few randomized trials directly compared the relative efficacy of tyrosine
kinase inhibitors (TKIs) in patients with advanced epidermal growth factor receptor (EGFR) …
kinase inhibitors (TKIs) in patients with advanced epidermal growth factor receptor (EGFR) …
[HTML][HTML] Weaving the next generation of (bio) materials: Semi-interpenetrated and interpenetrated polymeric networks for biomedical applications
Advances in polymer science have led to the development of semi-interpenetrated and
interpenetrated networks (SIPN/IPN). The interpenetration procedure allows enhancing …
interpenetrated networks (SIPN/IPN). The interpenetration procedure allows enhancing …
Localization of EGFR mutations in non-small-cell lung cancer tissues using mutation-specific PNA-DNA probes
H Shigeto, H Miyata, T Ashizawa… - Cancer Genomics & …, 2023 - cgp.iiarjournals.org
Abstract Background/Aim: Epidermal growth factor receptor (EGFR) signaling inhibitors are
potent therapeutic agents for EGFR-mutant non-small-cell lung cancer, but the effects of …
potent therapeutic agents for EGFR-mutant non-small-cell lung cancer, but the effects of …
Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of …
HC Chang, KT Huang, CC Tseng, YM Chen… - Thoracic …, 2023 - Wiley Online Library
Background The comparative efficacies of different generation tyrosine kinase inhibitors
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
[HTML][HTML] A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in Japanese patients with non-small cell lung cancer
A Fujiwara, M Yoshida, H Fujimoto, H Nakahara… - Oncology …, 2018 - ncbi.nlm.nih.gov
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …
[HTML][HTML] The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
A Topcu, A Ozturk, I Yurtsever, M Besiroglu… - Bosnian journal of …, 2022 - ncbi.nlm.nih.gov
Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with
epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is …
epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is …
[HTML][HTML] Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component …
Background Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …
exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and …